Health Care · Laboratory Analytical Instruments

ALMR Alamar Biosciences Inc SEC Filings & Insider Trading Activity 2026

company
CIK 210420429 filings

ALMR at a glance

Alamar Biosciences Inc (ALMR, SEC CIK 2104204) filed a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Alamar Biosciences Inc (ALMR) shares worth $164.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Qiming Corporate GP VI, Ltd. on November 11, 2026 of 582 shares at $30.63 per share.
  • In the last 90 days, ALMR insiders reported 0 open-market purchases ($0) and 128 open-market sales ($47.5M) on Form 4, a net sale of $47.5M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 128 sells
Net −$47.5M
13F holders
22 funds
$164.0M · +1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02 · Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • AI regulation risk: EU AI Act compliance may impose fines up to €35 million or 7% of worldwide annual turnover
  • FDA compliance risk: QMSR replaced QSR in February 2026, potentially increasing medical-device compliance costs
  • Funding demand risk: NIH’s 15% indirect-cost cap could reduce research budgets available for product purchases
  • Supply concentration risk: single-source antibodies face lead times of several months or more
  • Liquidity risk: $60 million revolving facility matures July 1, 2029, with no outstanding borrowings at September 30, 2026

Management Discussion & Analysis

  • Q3 revenue $33.5M, up $13.6M YoY, driven by product revenue growth to $26.3M
  • Consumables best performer: $17.8M, up 79% YoY, versus instruments $8.5M, up 50%
  • Gross margin 61.5% vs 59.7% YoY, while net loss widened to $13.3M from $8.0M
  • Cash, equivalents and short-term investments $226.6M, with operating cash outflow of $46.4M for nine months
  • Outlook: continued operating losses, higher R&D and SG&A, full-year 2026 stock compensation of $13M to $15M

AI summary of the ALMR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the company’s reported financial results

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • President Timothy “Tod” White retiring effective December 31, 2026 after more than five years
  • Six-month consulting arrangement through June 30, 2027 supports leadership transition and operational continuity

Item EX-99.1: Item EX-99.1

  • Q3 revenue $33.5M, up 68% year over year, led by consumables growth of 79% to $17.8M
  • Gross margin improved to 61.5% from 59.7%, but operating expenses rose 81% to $35.8M
Filed Sep 1, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Robert Ragusa appointed Class I director effective September 1, 2026, term expiring at the 2027 Annual Meeting
  • Board committee assignments span Audit, Compensation, and Nominating and Corporate Governance Committees
Filed Aug 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release Exhibit 99.1 contains the reported financial figures and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 2026 revenue $29.4M, up 82% year over year, led by consumables revenue growth of 147% to $15.5M
  • Gross margin improved to 60% from 53%, reflecting manufacturing efficiencies and higher-margin consumables mix

AI summaries of ALMR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALMR

Don't miss the next ALMR filing

  • Alerts as it files. A push when ALMR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALMR, by share count.
  • Ask anything. An AI agent that reads every ALMR filing and answers with sources.

ALMR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$30.63
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$29.34
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$29.34
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$30.63
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$29.34
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$30.63
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$29.34
Qiming Corporate GP VI, Ltd.SellNov 11, 2026$30.63

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALMR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALMR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$164.0M
Q2 202621$157.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 43 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALMR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 13, 2026--
4Nov 5, 2026--
10-QNov 4, 2026Analysis
8-KNov 3, 2026Analysis-
4Nov 3, 2026--
4Oct 29, 2026--
4Oct 27, 2026--
4Oct 23, 2026--
4Oct 21, 2026--
4Oct 19, 2026--
4Sep 16, 2026--
4Sep 3, 2026--
8-KSep 1, 2026Analysis-
10-QAug 11, 2026-
8-KAug 10, 2026Analysis-
8-KJul 15, 2026Analysis-
8-KMay 8, 2026-
10-QMay 8, 2026-
4Apr 22, 2026--
4Apr 20, 2026--
4Apr 20, 2026--
4Apr 20, 2026--
4Apr 20, 2026--
4Apr 20, 2026--

Related Health Care companies

All Health Care →

ALMR SEC filings: frequently asked questions

Are ALMR insiders buying or selling?

In the last 90 days, Alamar Biosciences Inc (ALMR) officers, directors and 10% owners reported no open-market purchases and 128 open-market sales worth $47.5 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALMR stock?

As of September 30, 2026, the largest Alamar Biosciences Inc (ALMR) holders among the 13F filers tracked by SignalX were ARK Investment Management ($42.3 million), BlackRock ($30.6 million), Vanguard Capital Management LLC ($15.4 million), Ameriprise Financial ($15.3 million), T. Rowe Price Group ($12.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ALMR report in its latest 8-K?

Alamar Biosciences Inc (ALMR) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest ALMR SEC filings?

Alamar Biosciences Inc (ALMR) filed a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 19, 2026.

What is ALMR's SEC CIK number?

Alamar Biosciences Inc (ALMR)'s SEC Central Index Key (CIK) is 2104204. EDGAR lists every ALMR filing under that number.

Ask anything about ALMR

The research agent reads ALMR's filings, financials, insider trades and 13F holders, then answers with sources.